Chengdu Tianfu International Bio-Town Investment & Development
VC Fund
Chengdu, China
Chengdu Tianfu International Bio-Town Investment & Development is a VC fund in Chengdu focused on Medical and Health Care. Chengdu International Bio-Town Investment and Development co., Ltd. is a joint venture established by Chengdu Hi-Tech Industrial Development Zone and Shuangliu District, was founded on May 10, 2016 with the registered capital of CNY 1.5 billion. It’s responsible for the infrastructure construction, supporting construction, industrial investment,and operation of the 44 km² Chengdu Tianfu International Bio-Town.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 45%
Last updated:
For AI agents: llms.txt
Industries Chengdu Tianfu International Bio-Town Investment & Development invests in
Stages Chengdu Tianfu International Bio-Town Investment & Development invests in
Countries Chengdu Tianfu International Bio-Town Investment & Development invests in
Investment Focus
Industry
- Medical 8 (73%)
- Health Care 6 (55%)
- Biotechnology 6 (55%)
- Manufacturing 3 (27%)
- Medical Device 2 (18%)
Stage
- Series A 4 (36%)
- Angel 3 (27%)
- Series C 2 (18%)
- Seed 1 (9%)
- Series B 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Mairui Medical
|
Mairui Medical is an innovative company focusing on the fields of oncology and neurology. | Seed / Nov 20, 2025 | |
NamiXin
|
NanoRibo is an innovative biopharmaceutical developer, focusing on cutting-edge biopharmaceuticals and new vaccine research and development. | Series A / Feb 10, 2025 | |
iRegene
|
iRegene researches and develops pharmaceutical therapy for neurodegenerative and rare diseases. | $14.1M / Series B / Oct 14, 2024 | |
New Radiomedicine Technology
|
Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting.In April 2016, the company was founded bythree co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy.The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 32.83 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT the most innovative technology enterprise in the radiopharmaceutical industry in China. | $41.7M / Series C / Mar 14, 2024 | |
Qitan Technology
|
Developer of a genome sequencing technology. The company takes advantage of nanopores to sequence single nucleic acid molecules.Using innovative nanopore gene sequencing technology, it provides single-molecule sequencing capability with long reading length, real-time output of sequencing results, low single-running cost, small and convenientinstrument, and cost-effective gene sequencing solution without complicated library preparation. It can directly detect the apparent modification of nucleic acids and expand the application of gene sequencing technology in cutting-edge biological research and clinical medicine such as instant diagnosis, metagenomics, epigenetics, RNA and transcriptomics. | $14.1M / Series C / Dec 28, 2023 | |
Gedent
|
Gedent is an orthodontics enterprise focused on the research and development of high-performance dental materials, artificial intelligence-assisted diagnosis systems, regenerative medical biological roots and other products | $15M / Angel / Jun 08, 2023 | |
Micron Bio
|
Micron Bio is a company that specializes in clever microfluidic manufacturing technologies. | Angel / Apr 16, 2023 | |
|
Microlon Biotechnology
|
Microlon Biotechnology is an innovative high-tech company that specializes in microfluidic intelligent manufacturing technologies. | Angel / Apr 16, 2023 | |
Siyi Intelligence
|
Established in 2017, Siyi Intelligence specializes in the design, development and commercialization of cutting-edge solutions in rehabilitation. Leading in know-how and technology, Siyi offers best-in-class products and reliable services for both clinical and home/community use. Our portfolio includes Syrebo® soft robotic hand rehabilitationglove, EasyWalk exoskeleton walking suit for lower extremity augmentation, EEG-based assistive BCIs, and Transcutaneous Electrical Nerve Stimulation devices and accessories, etc. Leveraging an extensive distribution network, our products have been marketed globally in over 80 countries and regions, serving a huge customer base of 3000 clinics and 30,000 households. Combining avantgarde technology, ease-of-use and affordability, Siyi is devoted to providing high performance rehabilitation products and making the innovative rehabilitation services available to all. | $15M / Series A / Mar 06, 2023 | |
Ucello Therapeutics
|
Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20. | $25M / Series A / Feb 10, 2022 | |
| See all 11 investments → | |||
Co-Investors
Chengdu High-tech Ceyuan Capital
2 deals together
Zhongjin Qianhai Development Fund
2 deals together
Canton Venture Capital
1 deal together
Chengdu Science and Technology Venture Capital
1 deal together
Cowin Venture
1 deal together
DT Capital Partners
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Chengdu Tianfu International Bio-Town Investment & Development invest in?
Chengdu Tianfu International Bio-Town Investment & Development invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Angel stage. Most of the 11 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Chengdu Tianfu International Bio-Town Investment & Development last invest?
The most recent investment recorded for Chengdu Tianfu International Bio-Town Investment & Development closed in Nov 2025. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
